Skip to main content
. 2003 Apr 1;3(1):1–72.

Table 6: Comparison of Patient Survival Rates at Miami University Hospital.

Patient survival rates 6 months 1 year
Period I (6/94-12/97, cyclophosphamide, OK3, MMF) n=44 53% 48%
Period II (6/98-01/00, daclizumab) n=53 79% 66%
Period III (01/00-08/01, Campath-1H in adults) n=23 89% ongoing